News

EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …

Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics …

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients

Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience

Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy